Growth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for Aneuploidy
Abstract Background Studies have shown that supplementation with recombinant human GH (rh-GH) during ovarian stimulation (OS) may improve the ovarian response and clinical outcomes of IVF. However, it remains unclear whether GH is associated with the ploidy status of embryos, and therefore, is unabl...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13048-023-01279-y |
| _version_ | 1827709011159416832 |
|---|---|
| author | Yilun Sui Min Xiao Jing Fu Lu Li Yining Xu Caixia Lei Xiaoxi Sun |
| author_facet | Yilun Sui Min Xiao Jing Fu Lu Li Yining Xu Caixia Lei Xiaoxi Sun |
| author_sort | Yilun Sui |
| collection | DOAJ |
| description | Abstract Background Studies have shown that supplementation with recombinant human GH (rh-GH) during ovarian stimulation (OS) may improve the ovarian response and clinical outcomes of IVF. However, it remains unclear whether GH is associated with the ploidy status of embryos, and therefore, is unable to explain the underlying reason for the effect of GH on IVF outcomes. This study aimed to investigate whether GH supplementation in women with advanced maternal age (AMA) during OS is related to an increased probability of obtaining euploid blastocysts. Methods This was a single center retrospective cohort study. The data of all women aged 38–46 years who underwent their first preimplantation genetic testing for aneuploidy (PGT-A) cycle between January 2021 and June 2022 were reviewed. Patients in the GH group received 4 IU/day subcutaneous GH supplementation from the beginning of OS to the trigger day, and patients in the control group did not. A total of 140 patients in the GH group and 272 patients in the control group were included after 1:2 propensity score matching. Results The baseline and cycle characteristics between the two groups were similar. The proportion of cycles which obtained euploid blastocysts was significantly higher in the GH group than that in the control group (41.43% vs. 27.21%, P = 0.00). The GH group had a significantly higher euploid blastocyst rate per cohort (32.47% vs. 21.34%, P = 0.00) and mean euploid blastocyst rate per cycle (per biopsy cycle 0.35 ± 0.40 vs. 0.21 ± 0.33, P = 0.00; per OS cycle 0.27 ± 0.38 vs. 0.16 ± 0.30, P = 0.02). However, the benefit of GH was more significant in patients aged 38–40 years, but not significant in patients aged 41–46 years. Pregnancy outcomes were similar between the two groups after embryo transfer. Conclusions GH supplementation during OS is associated with a significantly increased probability of obtaining euploid blastocysts in women aged 38–40 years, but this benefit is not significant in women aged 41–46 years. Our results explained the underlying reason for the effect of GH on IVF outcomes in existing studies, and might be helpful for AMA patients undergoing PGT-A cycles to obtain a better outcome meanwhile to avoid over-treatment. Trial registration NCT05574894, www.clinicaltrials.gov . |
| first_indexed | 2024-03-10T17:14:59Z |
| format | Article |
| id | doaj.art-3083f875c4f6421d9333dffafa20c438 |
| institution | Directory Open Access Journal |
| issn | 1757-2215 |
| language | English |
| last_indexed | 2024-03-10T17:14:59Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj.art-3083f875c4f6421d9333dffafa20c4382023-11-20T10:32:27ZengBMCJournal of Ovarian Research1757-22152023-10-0116111110.1186/s13048-023-01279-yGrowth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for AneuploidyYilun Sui0Min Xiao1Jing Fu2Lu Li3Yining Xu4Caixia Lei5Xiaoxi Sun6Shanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan UniversityShanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan UniversityShanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan UniversityShanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan UniversityShanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan UniversityShanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan UniversityShanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan UniversityAbstract Background Studies have shown that supplementation with recombinant human GH (rh-GH) during ovarian stimulation (OS) may improve the ovarian response and clinical outcomes of IVF. However, it remains unclear whether GH is associated with the ploidy status of embryos, and therefore, is unable to explain the underlying reason for the effect of GH on IVF outcomes. This study aimed to investigate whether GH supplementation in women with advanced maternal age (AMA) during OS is related to an increased probability of obtaining euploid blastocysts. Methods This was a single center retrospective cohort study. The data of all women aged 38–46 years who underwent their first preimplantation genetic testing for aneuploidy (PGT-A) cycle between January 2021 and June 2022 were reviewed. Patients in the GH group received 4 IU/day subcutaneous GH supplementation from the beginning of OS to the trigger day, and patients in the control group did not. A total of 140 patients in the GH group and 272 patients in the control group were included after 1:2 propensity score matching. Results The baseline and cycle characteristics between the two groups were similar. The proportion of cycles which obtained euploid blastocysts was significantly higher in the GH group than that in the control group (41.43% vs. 27.21%, P = 0.00). The GH group had a significantly higher euploid blastocyst rate per cohort (32.47% vs. 21.34%, P = 0.00) and mean euploid blastocyst rate per cycle (per biopsy cycle 0.35 ± 0.40 vs. 0.21 ± 0.33, P = 0.00; per OS cycle 0.27 ± 0.38 vs. 0.16 ± 0.30, P = 0.02). However, the benefit of GH was more significant in patients aged 38–40 years, but not significant in patients aged 41–46 years. Pregnancy outcomes were similar between the two groups after embryo transfer. Conclusions GH supplementation during OS is associated with a significantly increased probability of obtaining euploid blastocysts in women aged 38–40 years, but this benefit is not significant in women aged 41–46 years. Our results explained the underlying reason for the effect of GH on IVF outcomes in existing studies, and might be helpful for AMA patients undergoing PGT-A cycles to obtain a better outcome meanwhile to avoid over-treatment. Trial registration NCT05574894, www.clinicaltrials.gov .https://doi.org/10.1186/s13048-023-01279-yGrowth hormoneAdvanced maternal agePreimplantation genetic testing for aneuploidyEuploidyIn vitro fertilization |
| spellingShingle | Yilun Sui Min Xiao Jing Fu Lu Li Yining Xu Caixia Lei Xiaoxi Sun Growth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for Aneuploidy Journal of Ovarian Research Growth hormone Advanced maternal age Preimplantation genetic testing for aneuploidy Euploidy In vitro fertilization |
| title | Growth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for Aneuploidy |
| title_full | Growth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for Aneuploidy |
| title_fullStr | Growth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for Aneuploidy |
| title_full_unstemmed | Growth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for Aneuploidy |
| title_short | Growth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for Aneuploidy |
| title_sort | growth hormone supplementation during ovarian stimulation in women with advanced maternal age undergoing preimplantation genetic testing for aneuploidy |
| topic | Growth hormone Advanced maternal age Preimplantation genetic testing for aneuploidy Euploidy In vitro fertilization |
| url | https://doi.org/10.1186/s13048-023-01279-y |
| work_keys_str_mv | AT yilunsui growthhormonesupplementationduringovarianstimulationinwomenwithadvancedmaternalageundergoingpreimplantationgenetictestingforaneuploidy AT minxiao growthhormonesupplementationduringovarianstimulationinwomenwithadvancedmaternalageundergoingpreimplantationgenetictestingforaneuploidy AT jingfu growthhormonesupplementationduringovarianstimulationinwomenwithadvancedmaternalageundergoingpreimplantationgenetictestingforaneuploidy AT luli growthhormonesupplementationduringovarianstimulationinwomenwithadvancedmaternalageundergoingpreimplantationgenetictestingforaneuploidy AT yiningxu growthhormonesupplementationduringovarianstimulationinwomenwithadvancedmaternalageundergoingpreimplantationgenetictestingforaneuploidy AT caixialei growthhormonesupplementationduringovarianstimulationinwomenwithadvancedmaternalageundergoingpreimplantationgenetictestingforaneuploidy AT xiaoxisun growthhormonesupplementationduringovarianstimulationinwomenwithadvancedmaternalageundergoingpreimplantationgenetictestingforaneuploidy |